Results 11 to 20 of about 63,667 (225)

MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. [PDF]

PLoS ONE, 2013
Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection have demonstrated variable efficacy in men and women prompting assessment of variation in drug concentration as an explanation.
Craig W Hendrix, Beatrice A Chen, Vijayanand Guddera, Craig Hoesley, Jessica Justman, Clemensia Nakabiito, Robert Salata, Lydia Soto-Torres, Karen Patterson, Alexandra M Minnis, Sharavi Gandham, Kailazarid Gomez, Barbra A Richardson, Namandje N Bumpus   +13 more
doaj   +34 more sources

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide [PDF]

Journal of the International Association of Providers of AIDS Care (JIAPAC), 2020
HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to control viral replication and prevent complications.
Chanie Wassner, Nicole Bradley, Yuman Lee   +2 more
openaire   +3 more sources

Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV

Viruses, 2023
Tenofovir has been hypothesized to be effective against COVID-19 and is available as two prodrugs, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), both part of antiretroviral therapy (ART) regimens.
María F. Rombini, Diego Cecchini, Sofía Diana Menendez, Liliana Calanni, Rosana Cuini, Elena Obieta, María M. Greco, Fabricio Morales, Laura Morganti, Claudia Migazzi, Yasmin El Kozah, Pablo Parenti, Isabel Cassetti, on behalf of the COVIDARE Study Team   +13 more
doaj   +1 more source

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population

CPT: Pharmacometrics & Systems Pharmacology, 2023
Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are prodrugs of the nucleotide analogue tenofovir, which acts intracellularly to inhibit HIV replication.
Aida N. Kawuma, Roeland E. Wasmann, Phumla Sinxadi, Simiso M. Sokhela, Nomathemba Chandiwana, Willem D. F. Venter, Lubbe Wiesner, Gary Maartens, Paolo Denti   +8 more
doaj   +1 more source

Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study

Frontiers in Pharmacology, 2023
Background/aim: Tenofovir amibufenamide (TMF) has shown potent antiviral efficacy in randomized clinical studies. This study aimed to reveal the effectiveness and safety of tenofovir amibufenamide in the real world and compared tenofovir amibufenamide to
Lanqing Li, Jing Zhou, Yujing Li, Fada Wang, Dongmei Zhang, Menglan Wang, Yachao Tao, Enqiang Chen   +7 more
doaj   +1 more source

Glucocorticoid-Induced Hypokalemic Periodic Paralysis after Short-Term Use of Tenofovir with Hypophosphatemia: A Case Report

Medicina, 2021
Hypokalemic periodic paralysis (HPP) is a neuromuscular disorder associated with muscular dysfunction caused by hypokalemia. There are various causes of HPPs and rarely, HPP appears to be relevant to tenofovir or glucocorticoid treatment. There have been
Yujin Shin, Yonglee Kim, Kyong Young Kim, Jong Ha Baek, Soo Kyoung Kim, Jung Hwa Jung, Jong Ryeal Hahm, Min Young Kim, Jaehoon Jung, Hosu Kim   +9 more
doaj   +1 more source

Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. [PDF]

PLoS ONE, 2011
The Bangkok Tenofovir Study was launched in 2005 to determine if pre-exposure prophylaxis with tenofovir will reduce the risk of HIV infection among injecting drug users (IDUs). We describe recruitment, screening, enrollment, and baseline characteristics
Michael Martin, Suphak Vanichseni, Pravan Suntharasamai, Udomsak Sangkum, Rutt Chuachoowong, Philip A Mock, Manoj Leethochawalit, Sithisat Chiamwongpaet, Somyot Kittimunkong, Frits van Griensven, Janet M McNicholl, Lynn Paxton, Kachit Choopanya, Bangkok Tenofovir Study Group   +13 more
doaj   +1 more source

Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. [PDF]

PLoS ONE, 2013
Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized.
Cristina Gervasoni, Paola Meraviglia, Simona Landonio, Sara Baldelli, Serena Fucile, Laura Castagnoli, Emilio Clementi, Agostino Riva, Massimo Galli, Giuliano Rizzardini, Dario Cattaneo   +10 more
doaj   +1 more source

Tenofovir alafenamide fumarate

Antiviral Therapy, 2022
Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue resulting in high concentrations of tenofovir (TFV) and its active diphosphate metabolite inside the cells that replicate HIV. Due
William A Lee, Andrew K Cheng
doaj   +1 more source

Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients. [PDF]

, 2017
BackgroundThe antiretroviral medication, tenofovir disoproxil fumarate (TDF), is used by most human immunodeficiency virus-infected persons in the United States despite higher risks of chronic kidney disease.
Chen, Ruijun, Estrella, Michelle M, Grunfeld, Carl, Horberg, Michael A, Hsue, Priscilla Y, Jotwani, Vasantha, Scherzer, Rebecca, Shlipak, Michael G   +7 more
core   +1 more source